Pharmaceutical company Jubilant Life Sciences reported revenue growth of 31% for the quarter ended June 30, and an operating profit growth of 46%, year-on-year.
The company’s income from operations was at an all-time high of Rs 1,240 crore in April-June. The growth was backed by overall volume increase of 23%.
“Our strategy of geographic expansion is yielding fruits in terms of 37% growth in international revenues,” said Shyam S Bhartia, chairman and managing director and Hari S Bhartia, co-chairman and managing director, Jubilant Life Sciences.
“The exceptional performance has been driven by focus to continuously move up the value chain and launch new products through innovative processes,” they said. The company expects a robust revenue and profit growth with stable EBITDA margins in times to come.
In 2012-13, the company is confident of achieving 20-22% revenue growth on account of new product launches and expansion in new territories.